Skip to content
Catalyst

berberineFinding

Berberine decreases interleukin‑6 concentration

lowersModerate evidenceFindingreplicated ×1

01 · The sentence it was drawn from

“The pooled findings using random-effects model showed that berberine use in patients with MetS and related disorders significantly decreased the concentration level of CRP (SMD = − 1.54; 95% CI − 1.86, − 1.22; p < 0.05), TNF-α (SMD = − 1.02; 95% CI − 1.27, − 0.77; p < 0.05), and IL-6 (SMD = − 1.17; 95% CI − 1.53, − 0.81; p < 0.05).”
Quoted verbatim from The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials.
This finding among the 81 findings on its endpoint

berberine

Interleukin-6 concentration

lowers

Effect as reported

−1.17standardised mean difference

CI −1.53 to −0.81

Who
Chinese patients with metabolic syndrome and related disorders (diabetes, diabetic nephropathy, cardiovascular disease, polycystic ovary syndrome and others) in pooled RCTs; berberine mostly added to background drug therapy that the control arm also received, with placebo, no treatment or another drug as comparator
Dose studied
berberine 0.09 g to 1.8 g daily across trials

Moderate evidencePMID 35352233 · 2022

02 · The study

Study
meta-analysis
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

Inflammopharmacology
What else it reported3 findings · 1 compound · 3 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZAE6EB840PPD2VWW88ZW0Y